RxDoctor Payments Data

Danielle Blake, MD

Otolaryngology · West Orange, NJNPI 1396159620

Payments from drug & device makers

$2,583in general payments, 2019–2025

Across 144 payments — averaging $17.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$671
  • GSK$575
  • Regeneron Healthcare Solutions, Inc.$350
  • Optinose US, Inc.$349
  • Aerin Medical Inc.$200
  • Sanofi-aventis U.S. LLC$99
  • plus $339 from 10 others

What the payments were for

  • Food & beverage$2,45095%
  • Education$1335%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,583 in reported general payments places this provider in the 70th percentile of 232 otolaryngology providers in New Jersey.

See all otolaryngology providers in New Jersey

Medicare billing

Part B allowed, 2024
$247,848
Medicare patients
806
Services billed
2,485

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab16$58,618
XhanceFluticasone Propionate12$10,386
Ipratropium Bromide113$3,350
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth17$2,224
Fluocinolone Acetonide Oil34$1,449
Fluticasone Propionate46$787
Pantoprazole Sodium44$756
Famotidine53$633
Azelastine Hcl12$576
Montelukast Sodium35$553
Ofloxacin20$259
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav23$247
Mupirocin34$237
Methylprednisolone27$160
Prednisone30$151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$349$10,38612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 232 otolaryngology providers in New Jersey.

Other otolaryngology in West Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →